What Is MSS Cancer and How Is It Treated?

MSS cancer, short for microsatellite stable cancer, is a tumor whose DNA mismatch repair system functions normally, leaving its microsatellite regions (short, repetitive stretches of DNA) intact and uniform. The label matters most in colorectal cancer, where roughly 85 percent of cases are MSS. That distinction carries enormous treatment implications: the immune checkpoint inhibitors that produce dramatic responses in microsatellite-unstable tumors have so far shown little benefit for MSS patients, pushing oncologists toward chemotherapy-based regimens and, increasingly, toward experimental combination strategies designed to break through the immune resistance that defines these tumors.

What “Microsatellite Stable” Actually Means

Every cell in your body copies its DNA before dividing, and mistakes happen during that copying process. A set of proteins called the mismatch repair (MMR) system catches and fixes those errors. When that system works correctly, a tumor is classified as “proficient mismatch repair” (pMMR), and its microsatellite sequences stay consistent from cell to cell. That tumor is microsatellite stable. When the repair system breaks down, errors pile up in those repetitive sequences, producing what’s called microsatellite instability (MSI-high or MSI-H). In one study of multiple cancer types, nearly all MSS tumors still expressed both key repair proteins (hMLH1 and hMSH2), while the vast majority of MSI tumors had lost expression of at least one.¹

The practical upshot: MSI-high tumors tend to accumulate hundreds or thousands of mutations, producing unusual proteins (neoantigens) that the immune system can recognize. MSS tumors, with their functional repair machinery, carry far fewer mutations and generate fewer of those immune signals. This is the root of the treatment divide between the two groups.

How Doctors Test for MSS Status

Testing typically happens on a tissue sample from a biopsy or surgery. The two main approaches are immunohistochemistry (IHC), which stains the tissue to check whether the four key MMR proteins are present, and molecular testing, which directly examines microsatellite regions for instability. A 2022 guideline from the College of American Pathologists recommends IHC as the preferred method for colorectal, gastroesophageal, small bowel, and endometrial cancers when the goal is determining eligibility for immunotherapy.² IHC is widely available and relatively inexpensive, and it can pinpoint which specific repair protein is missing, which helps guide genetic counseling in hereditary cases.

Next-generation sequencing (NGS) has gained traction as an alternative, particularly because many cancer patients already undergo broad genomic profiling to look for targetable mutations. NGS-based methods can assess more microsatellite sites than older PCR-based panels, and they can flag MSI status as part of a single comprehensive test.³ The two methods usually agree, but discordant results do occur, and in those cases clinicians typically weigh IHC results more heavily for treatment decisions in colorectal cancer.

Why MSS Tumors Are “Cold” to the Immune System

Oncologists often describe MSS tumors as immunologically “cold.” The metaphor captures a real biological difference. Research comparing microsatellite-stable and microsatellite-unstable colon cancers found that MSI tumors had far more immune cells inside and around the tumor, including cytotoxic T cells (CD8+), helper T cells (CD4+), and macrophages. MSS tumors, by contrast, were relatively deserted.⁴

The reason traces back to mutation burden. Because MSS tumors generate fewer neoantigens, the immune system has less to react to. On top of that, MSS tumors tend to create an actively suppressive environment that keeps immune cells at bay.⁵ This combination of low neoantigen load, sparse T-cell infiltration, and dominant immunosuppressive signaling is what makes standard single-agent immunotherapy largely ineffective for these patients.⁶

Standard Treatment for MSS Colorectal Cancer

For the majority of people diagnosed with MSS colorectal cancer, treatment still centers on chemotherapy, often combined with a biologic agent tailored to the tumor’s location and genetic profile. The American Society of Clinical Oncology (ASCO) guideline for metastatic colorectal cancer recommends different first-line approaches depending on whether the tumor is left-sided or right-sided and whether it carries RAS mutations. For MSS, RAS wild-type tumors on the left side of the colon, the standard first-line is chemotherapy combined with anti-EGFR therapy. For right-sided MSS tumors, the recommendation is chemotherapy plus an anti-VEGF agent, which works by starving the tumor of its blood supply.⁷

These regimens can extend survival substantially compared to best supportive care alone, and many patients respond well initially. But for metastatic disease, the cancer eventually progresses through available chemotherapy lines for most patients, which is why the search for immunotherapy-based options for MSS tumors has become one of the most active areas in oncology research.

The Immunotherapy Problem

When immune checkpoint inhibitors like pembrolizumab and nivolumab first showed results in colorectal cancer, the responses were concentrated almost entirely among MSI-H patients. For MSS patients, clinical trials repeatedly came up empty. A review from ASCO put it bluntly: trials have not shown any substantial clinical benefit from checkpoint inhibitor therapy for microsatellite stable colorectal cancer.⁸

This matters beyond academic disappointment. Immunotherapy, when it works, can produce responses lasting years, sometimes amounting to a functional cure. Chemotherapy responses in metastatic colorectal cancer, while meaningful, are almost always temporary. So cracking the MSS immunotherapy problem could reshape outcomes for the vast majority of people with advanced colorectal cancer.

Combining Anti-Angiogenesis Drugs with Checkpoint Inhibitors

One of the most studied strategies for waking up the immune system in MSS tumors involves pairing checkpoint inhibitors with drugs that target tumor blood vessel formation. The logic: abnormal blood vessels in tumors create a hostile, oxygen-starved environment that suppresses immune activity. Anti-angiogenic drugs like regorafenib can normalize those vessels and shift the tumor microenvironment toward one that’s more hospitable to immune cells.

A phase 2 trial tested regorafenib combined with nivolumab in 70 patients with MSS metastatic colorectal cancer. The overall response rate was 7 percent, which sounds small, but something interesting emerged in the subgroup: among the 23 patients without liver metastases, the response rate jumped to 22 percent.⁹ A separate phase 1 trial testing regorafenib with both ipilimumab and nivolumab found a response rate of about 28 percent at the recommended dose, and for patients without liver metastases that rose to over 36 percent, with a median overall survival of more than 22 months.¹⁰

Molecular analysis of responders in these trials revealed that tumors responding to the regorafenib-nivolumab combination showed upregulation of genes related to the inflammatory response, cancer-associated fibroblasts, and immune signaling, along with a key target of regorafenib itself. In other words, the drug combination appeared to reshape the tumor environment in a way that allowed the immune system to engage.¹¹

A New Kind of Checkpoint Inhibitor Combination

Perhaps the most talked-about development for MSS colorectal cancer involves botensilimab and balstilimab, a pair of checkpoint inhibitors that work differently from existing options. Botensilimab is an Fc-enhanced anti-CTLA-4 antibody, meaning it was engineered to do more than just block the CTLA-4 checkpoint. It’s designed to directly activate immune cells in the tumor neighborhood. Balstilimab targets PD-1, the more familiar checkpoint.

In a phase 1 trial of 101 response-evaluable patients with MSS metastatic colorectal cancer, the combination produced an overall response rate of 17 percent, with a disease control rate of 61 percent. More striking was durability: the median duration of response had not been reached at the time of analysis, meaning most responders were still responding.¹² For a population where checkpoint inhibitors alone typically produce response rates near zero, these numbers generated genuine excitement in the field.

Preliminary results from a randomized phase 2 study further reinforced the signal. The combination outperformed botensilimab alone, and standard-of-care chemotherapy produced no objective responses, while most responses to the combination were still ongoing at analysis.¹³ A global phase 3 trial is now planned. Early reports from a neoadjuvant setting (giving the drugs before surgery) showed what researchers described as an “inside-out” pattern of tumor regression, where immune cells appeared to attack the cancer from the serosa inward toward the mucosal surface, after just one or two doses.¹⁴

Why Liver Metastases Change Everything

A pattern that recurs across nearly every immunotherapy trial in MSS colorectal cancer: patients whose cancer has spread to the liver respond far worse than those whose metastases are elsewhere. The liver itself appears to act as an immune suppressor. Research shows that liver metastases don’t just resist local immune attack; they reduce immune cell infiltration even in the primary tumor and at other metastatic sites throughout the body.¹⁵

This finding is consistent across multiple MSS colorectal cancer trials: the presence of liver metastases reliably lowers overall response rates compared to patients without liver involvement.¹⁶ A retrospective analysis confirmed that liver metastases are associated with inferior survival outcomes for MSS patients treated with checkpoint inhibitor-based therapies, lending support to the idea that the hepatic environment itself hampers the immune system’s ability to fight the cancer.¹⁷

This has practical consequences for clinical trial design and patient counseling. Many ongoing trials now stratify patients by liver metastasis status, and some enroll only patients without liver involvement. If you have MSS colorectal cancer and your oncologist discusses immunotherapy trials, the presence or absence of liver metastases is likely to be a major factor in eligibility and expected benefit.

Targetable Mutations Within MSS Tumors

While immunotherapy strategies receive the most attention, a parallel track focuses on specific genetic vulnerabilities within MSS tumors. Two of the most actionable are KRAS G12C mutations and BRAF V600 mutations. BRAF V600 mutations drive roughly 10 percent of colorectal cancers and require a different treatment approach than other subtypes. First-generation BRAF inhibitors alone don’t work well in colorectal cancer because the EGFR signaling pathway reactivates around the block, so effective regimens combine BRAF inhibitors with EGFR and MEK or ERK blockade.¹⁸

For KRAS G12C mutations, a newer class of drugs exploits a pocket in the mutant protein that can be targeted when the protein is in its inactive state. In colorectal cancer, where EGFR feedback limits how well these drugs work alone, combining KRAS G12C inhibitors with EGFR blockade and chemotherapy has shown meaningful activity. Newer strategies in development include paradox-breaking RAF inhibitors, pan-RAS inhibitors, and immunotherapy combinations that take advantage of the distinct immune features of certain MSS subtypes, particularly BRAF-mutant MSS tumors that tend to have a more immune-active phenotype than other MSS cancers.¹⁸

MSS Cancer Prognosis Compared to MSI-High

You might expect that MSI-high tumors, with their heavy mutation burden, would behave more aggressively. The picture is more nuanced. In a large Swedish multi-center study of colorectal cancer patients, MSS tumors had a higher rate of distant metastases within six years (about 20 percent versus 9 percent for MSI patients). Overall six-year survival was 68.5 percent for MSS compared to 74.2 percent for MSI. But statistically, the differences in overall mortality, cancer-specific mortality, and relapse-free survival did not reach significance.¹⁹

In early-stage disease (stage I and II), MSI-high status is generally associated with a better prognosis. The picture blurs in stage III, where chemotherapy benefits and recurrence patterns interact with MSI status in complicated ways. For stage IV disease, where immunotherapy becomes relevant, the MSI-high advantage widens again because those patients can access checkpoint inhibitors. The prognostic picture for MSS patients thus depends heavily on stage at diagnosis and which treatments are available.

Radiation as an Immune Primer

Another approach to converting a cold MSS tumor into one the immune system can see involves radiation therapy. When radiation kills tumor cells, it can trigger a form of cell death that releases signals alerting the immune system, essentially turning the dying cells into a vaccine against the surviving tumor. Preclinical work combining radiation with an ATR inhibitor called berzosertib showed that the combination activated STING signaling, a key pathway for triggering innate immune responses, and reinvigorated the cold tumor microenvironment in colorectal cancer models, making them more responsive to immunotherapy.²⁰

Other researchers are exploring whether inducing ferroptosis, a specific form of iron-dependent cell death, alongside radiation could convert MSS colorectal tumors from cold to hot. The strategy involves maximizing immune-alerting cell death while simultaneously blocking the tumor’s defenses against it.²¹ These remain early-stage, largely preclinical strategies. But they represent a fundamentally different philosophy from simply giving more powerful immune drugs: instead of trying harder to kick-start the immune response, they try to change the tumor itself so the immune system has something to respond to.

The Gut Microbiome Connection

An emerging thread in MSS colorectal cancer research involves the trillions of bacteria living in the gut. The gut microbiome can influence how well checkpoint inhibitors work, and this appears to be especially relevant for MSS tumors where the immune system needs every advantage it can get.²²

Research has identified specific microbial products that could tip the balance. Propionic acid, a short-chain fatty acid produced by certain gut bacteria, and the bacterium Bacteroides fragilis both improved CD8+ T-cell infiltration into MSS colorectal tumors in experimental models. The mechanism appears to involve epigenetic changes: propionic acid promotes a specific modification of histones (the proteins DNA wraps around), which activates a gene pathway that recruits killer T cells into the tumor.²³

A clinical trial combining the checkpoint inhibitor tislelizumab, the anti-angiogenic drug fruquintinib, and fecal microbiota transplantation in patients with refractory MSS metastatic colorectal cancer reported that most patients maintained stable or improved quality of life, with a median time to deterioration in global health status of about 8 months.²⁴ This is still early-stage evidence, and fecal transplants carry their own safety considerations, but the principle that modifying the gut microbiome could unlock immune responses in otherwise resistant tumors is gaining traction across multiple research groups.

MSS Beyond Colorectal Cancer

While the MSS distinction is most frequently discussed in the context of colorectal cancer, microsatellite status is relevant in other tumor types as well. Endometrial, gastric, ovarian, and small bowel cancers are all tested for MSI status, and the same basic divide applies: MSI-high tumors tend to respond to immunotherapy, while MSS tumors generally do not. One study examining gastric and colorectal cancers found that patients with microsatellite-unstable gastric cancer had a higher prevalence of synchronous colorectal neoplasms compared to those with MSS gastric cancer, suggesting that the underlying mismatch repair deficiency can affect multiple sites in the gastrointestinal tract simultaneously.²⁵

The treatment strategies being developed for MSS colorectal cancer, including anti-angiogenesis combinations and novel checkpoint inhibitor pairings, could eventually inform approaches to MSS tumors at other sites. But for now, the clinical trial infrastructure is most advanced in colorectal cancer, and patients with MSS tumors in other organs face an even thinner evidence base for immunotherapy options. Understanding your tumor’s microsatellite status remains one of the most consequential pieces of information in guiding treatment decisions, regardless of where in the body the cancer originates.